Efficacy and Safety Clinical Trial
Official title:
Prospective Clinical Study of Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
This study is a prospective clinical study. The purpose is to explore the efficacy and safety of Envafolimab combined with chemotherapy for neoadjuvant treatment or conversion treatment of locally advanced head and neck squamous cell carcinoma, and to observe the correlation between the immune microenvironment and the efficacy of immune checkpoint inhibitors, genetic changes and the efficacy in head and neck squamous cell carcinoma .
This study is a prospective clinical study. The purpose is to explore the efficacy and safety of Envafolimab combined with chemotherapy for neoadjuvant treatment or conversion treatment of locally advanced head and neck squamous cell carcinoma, and to observe the correlation between the immune microenvironment and the efficacy of immune checkpoint inhibitors, genetic changes and the efficacy in head and neck squamous cell carcinoma . After the patient signed the informed consent form, he was screened to meet the enrollment criteria and received envafolimab combined with chemotherapy according to the patient's condition. For the first imaging evaluation, if surgical treatment can be performed, neoadjuvant therapy is required to be enrolled in group A, and 3 cycles of chemotherapy combined with envafolimab are given for re-imaging after treatment. The iRECIST criteria were used to evaluate and observe the ORR and PRO (University of Washington Head and Neck Tumor Quality of Life Scale 4th Edition (UW-QOL V4.0)), if the clinical status of the subjects is stable and the investigator evaluates that surgical treatment is feasible, the subjects can be treated with surgery, and the MPR and pCR rates are observed in postoperative pathology. After the operation, the next treatment plan (adjuvant therapy or observation) is decided according to the patient's pathological condition. If the patient develops PD during the treatment period, the subject should discontinue the study treatment. If the imaging evaluation cannot be surgically treated, conversion therapy can be used to enroll in group B, and 3 cycles of chemotherapy combined with envafolimab can be given for re-imaging after treatment. The iRECIST criteria were used to evaluate and observe the ORR and PRO (University of Washington Head and Neck Tumor Quality of Life Scale 4th Edition (UW-QOL V4.0)), if the clinical status of the subjects is stable and the investigator evaluates that surgical treatment is feasible, the subjects can be treated with surgery, and the MPR and pCR rates are observed in postoperative pathology. After the operation, the next treatment plan (adjuvant therapy or observation) is decided according to the patient's pathological condition. If the patient develops PD during the follow-up period, the subject should discontinue the study treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04759534 -
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Not yet recruiting |
NCT05532111 -
Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial
|
N/A | |
| Active, not recruiting |
NCT04284215 -
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC
|
N/A | |
| Completed |
NCT06202456 -
A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver
|
Phase 4 | |
| Completed |
NCT04870606 -
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
|
Phase 3 | |
| Completed |
NCT03660761 -
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03794778 -
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
|
Phase 4 | |
| Recruiting |
NCT03255343 -
Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim
|
N/A | |
| Recruiting |
NCT04197544 -
Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.
|
N/A | |
| Recruiting |
NCT04518501 -
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03779776 -
The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants
|
N/A | |
| Enrolling by invitation |
NCT02809079 -
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
|
Phase 4 | |
| Active, not recruiting |
NCT06194188 -
A Phase 2 Clinical Study of CU-20401
|
Phase 2 | |
| Recruiting |
NCT03901235 -
MSC Intratissular Injection in Crohn Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03826004 -
Clemastine in Cardiovascular Surgery
|
N/A | |
| Active, not recruiting |
NCT03623776 -
Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.
|
Phase 2 | |
| Recruiting |
NCT04078399 -
Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence
|
N/A | |
| Not yet recruiting |
NCT06351735 -
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
|
||
| Not yet recruiting |
NCT06383078 -
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
|
Phase 2 | |
| Withdrawn |
NCT05481775 -
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
|
Phase 2 |